/PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative...

Related Keywords

Feng Wang , Hunan , China , Shanghai , Shenzhen , Guangdong , Chengdu , Sichuan , United States , Japan , Beijing , Taiwan , American , Chinese , Ruihua Xu , Sun Yat , Xianping Lu , Chidamide Tucidinostat , Chipscreen Biosciences , Weili Zhao , Chidamide Epidaza , Data Monitoring Committee , Chipscreen Biosciences United States Co Ltd , Prnewswire Shenzhen Chipscreen Biosciences Co Ltd , Chengdu Small Molecule Early Rd Center , Shanghai Jiao Tong University School Of Medicine , Chengdu Regional Head Office Rd Center , Shenzhen Chipscreen Biosciences Co Ltd , Shenzhen Small Molecule Early Rd Center , Innovative Drug Development , Shenzhen Head Office Rd Center , National Science , Treatment Center , National Medical Products Administration , American Society Of Clinical Oncology , Shanghai Branch , Stock Symbol , Independent Data Monitoring Committee , American Society , Clinical Oncology , Annual Meeting , General Manager , Professor Feng Wang , Cancer Prevention , Nature Medicine , Professor Weili Zhao , Ruijin Hospital , Shanghai Jiao Tong University School , Mainland China , Shenzhen Head , Chengdu Regional Head , Beijing Branch , Innovative Drug , Shenzhen Chipscreen Biosciences Co , Td ,